Sanofi’s Dupixent Gains EU Approval for Pediatric Eosinophilic Esophagitis
Sanofi (SNY) has released an update. Sanofi’s Dupixent has received EU approval as the first treatment for children aged one to 11 with ...
clinicaladvisor.com10h
Biologic Therapies for Psoriasis Linked to Increased GI Adverse Events
Researchers used pharmacovigilance data to examine the onset of gastrointestinal adverse events associated with the use of biologic therapies for psoriasis.
GlobalData on MSN13h
AstraZeneca and Amgen’s Tezspire succeeds in Phase III nasal polyps trial
The companies’ monoclonal antibody met co-primary endpoints in a Phase III trial in patients with chronic rhinosinusitis with ...
FiercePharma11h
AstraZeneca, Amgen's Tezspire scores in rhinosinusitis study
TSLP is released in response to allergens, viruses and other airborne particles associated with asthma, COPD, CRSwNP, ...
Celldex’s Strategic Focus on Barzolvolimab Drives Buy Rating Amid Promising Clinical Advancements
Leerink Partners analyst Thomas Smith has reiterated their bullish stance on CLDX stock, giving a Buy rating yesterday. Thomas Smith’s ...
Le Lézard19h
TEZSPIRE MET BOTH CO-PRIMARY ENDPOINTS IN PHASE 3 TRIAL FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
Amgen and AstraZeneca today announced positive top-line results from the Phase 3 WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP [nasal polyps]). The trial ...
EuropaWire11h
Tezspire Shows Promise in Reducing Nasal Polyp Symptoms in Phase III Trial for Chronic Rhinosinusitis
17,18 TSLP is released in response to multiple triggers (including allergens, viruses and other airborne particles) ...